TKI adherence is critical, and TKI impact on daily life
may affect adherence1-4
In a survey of patients with CML-CP, AEs were a major reason for missing doses1
Many patients with CML skip doses without consulting their HCP because of how treatment makes them feel—despite the risk of decreased efficacy.1-4
*In a US survey (70 patients, 30 physicians) investigating the unmet needs around CML and treatment switching in patients who had received 1 to 3 prior TKIs.1
In a separate study, 52% said their treatment had interfered with their QOL during the preceding year.5,†
†Among 832 patients with CML who were experiencing low-grade AEs. Patients were treated for a median duration of 5.8 years.5
Patients with higher rates of adherence were more likely to achieve deeper responses3
For patients with an adherence rate of >90%, the 6-year probability of achieving MMR with a 1st TKI was 93.7%.3
Six-year probability of achieving MMR, MR4, and CMR in patients with CML on a 1st TKI with different levels of adherence3
A study of 87 patients with CML-CP who had achieved complete cytogenetic response had adherence monitored during a 3-month period by using a microelectronic monitoring device to determine the association between adherence and molecular response.3
Patients with an adherence rate of >85% had lower probability of progression on their 1st TKI6
24-month probability of EFS in patients with Ph+ CML-CP on a TKI and an adherence rate of ≤85% (n=18) or >85% (n=69)6,‡
‡In a study of 87 patients with CML, the relationship between adherence and probability of EFS were evaluated. Adherence levels were monitored using a medication event-monitoring (an electronic device fitted into the cap of a normal-looking medication bottle that automatically records each time the bottle is opened). After 3 months of monitoring, patients were followed subsequently for a median of 19 months (range, 14-24 months).6
Making plans is tough because of how treatment sometimes makes me feel.
–Actual CML patient
See why choosing the right TKI for your patient matters
AE, adverse event; AP, accelerated phase; BC, blast crisis; CCyR, complete cytogenetic response; CHR, complete hematologic response; CML, chronic myeloid leukemia; CML-CP, chronic myeloid leukemia in chronic phase; CMR, complete molecular response; EFS, event-free survival; MMR, major molecular response; MR, molecular response; QOL, quality of life; TKI, tyrosine kinase inhibitor.
References: 1. Clements J, Ruiz C, Damon A, et al. Poster presentation at: SOHO 2023 Eleventh Annual Meeting; September 6-9, 2023; Houston, TX, and virtual. 2. Noens L, Jensen M, Kucmin-Bemelmans I, et al. Haematologica. 2014;99(3)437-447. 3. Marin D, Bazeos A, Mahon F-X, et al. J Clin Oncol. 2010;28(14):2381-2388. 4. de Almeida MH, Fogliatto L, Couto D. Rev Bras Hematol Hemoter. 2014;36(1):54-59. 5. Gambacorti-Passerini C, Antolini L, Mahon F-X, et al. J Natl Cancer Inst. 2011;103(7):553-561. 6. Ibrahim AR, Eliasson L, Apperley JF, et al. Blood. 2011;117(14):3733-3736.